Senhwa Biosciences, Inc. (6492.TWO)

TWD 42.5

(0.47%)

Market Cap (In TWD)

3.79 Billion

Revenue (In TWD)

1 Million

Net Income (In TWD)

-296.3 Million

Avg. Volume

999.69 Thousand

Currency
TWD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
40.35-64.5
PE
-
EPS
-
Beta Value
0.968
ISIN
TW0006492002
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Jin-Ding Huang Ph.D.
Employee Count
-
Website
https://www.senhwabio.com
Ipo Date
2014-12-04
Details
Senhwa Biosciences, Inc., a drug development company, engages in the development of new drugs and targeted agents. The company develops CX-5461, a phase I, open-label, dose escalation, safety, pharmacokinetic, and pharmacodynamics study of intravenously administered CX-5461 in patients with advanced hematologic malignancies; CX-5461, which is in a phase I study for solid tumors; CX-5461 that is in a phase Ib expansion study of CX-5461 in patients with solid tumors and BRCA2 and /or PALB2 mutation; and CX-5461, which is in Phase I trial of pidnarulex and talazoparib in patients with metastatic castration resistant prostate cancer. It is also developing CX-4945-CCA that is in phase I/II clinical trial in combination with gemcitabine for the treatment of patients with cholangiocarcinoma; CX-4945-BCC, which is in phase I, multi-center, open-label, treatment duration increment, expansion, safety, and pharmacodynamic study of CX-4945 administered orally twice daily to patients with advanced basal cell carcinoma; and CX-4945-MB, a pediatric brain tumor consortium that is in phase I/II and surgical study of CX-4945 in patients with recurrent SHH medulloblastoma. In addition, the company develops CX-4945-AV06, a phase II, double blind randomized, controlled study to evaluate the safety and efficacy of CX-4945 in hospitalized adults with COVID-19. Senhwa Biosciences, Inc. was incorporated in 2012 and is based in New Taipei City, Taiwan.